{"url_path":"/sec/crdf/8-k/2026-06-03/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-254658-index.html","accession_number":"0001193125-26-254658","cik":"0001213037","ticker":"CRDF","issuer_name":"Cardiff Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1213037/0001193125-26-254658-index.html","primary_entity_key":"0001213037","primary_entity_name":"Cardiff Oncology, Inc."},"word_count":159,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nCardiff Oncology, Inc. prepared an investor presentation reviewing its Phase 2 CRDF-004 data and registrational study plans for onvansertib. A copy of the presentation materials is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference..\n\n \n\nThe information in this report, including the investor presentation furnished as Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. In addition, the exhibit furnished herewith contain statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in such exhibit."}